Join collection
Hello, welcome to our official website!
Hansen Pharmaceuticals and Atomwise Launch Strategic Collaboration on Artificial Intelligence Drug Discovery in Multiple Therapeutic Areas
2019-09-16

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.

Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.

Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."

Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."

The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.

Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.

2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.

Official registration and consultation channels:

ContactAnn

Phone: 021-65650305

EmailMarketing@zenseegroup.com

http://www.zenseegroup.com/forms/view/22113/


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in OncologyWEDNESDAY, OCTOBER 16, 2019CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful drug discovery engine to achieve higher probabilities of success in drug development, today announced a license agreement whereby CRISPR Therapeutics will gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs, and KSQ will gain access to CRISPR Therapeutics’ IP for editing novel gene targets identified by KSQ as part of its current and future eTILTM (engineered tumor infiltrating lymphocyte) cell programs. The financial terms of the agreement are not being disclosed.“We are thrilled to gain access to CRISPR Therapeutics’ foundational IP estate through this agreement,” said David Meeker, M.D., Chief Executive Officer at KSQ Therapeutics. “Our eTILTM programs involve editing gene targets in human TILs that were discovered at KSQ by applying our proprietary CRISPRomics® approach to immune cells in multiple in vivo models. This agreement clears an important path for us to be able to bring these programs through development and commercialization, leveraging CRISPR Therapeutics’ proprietary editing technology.”The gene targets within the scope of the license agreement were identified using KSQ’s proprietary CRISPRomics® drug discovery engine, which allows genome-scale, in vivo validated, unbiased drug discovery. These specific targets were uncovered in screens to identify genetic edits that could enhance the functionality and quality of adoptive cell therapies in oncology.“KSQ has built an industry-leading platform to screen for novel gene targets using its technology, and has identified a group of targets that could help unlock the full potential of adoptive cell therapy in oncology,” said Samarth Kulkarni, Ph.D., Chief Executive Officer at CRISPR Therapeutics. “As a result of this license agreement, CRISPR Therapeutics will have the opportunity to bring these novel targets into our leading allogeneic CAR-T development platform to further strengthen our future programs in this important therapeutic area.”information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/crispr-therapeutics-and-ksq-therapeutics-announce-license-agreement-to-advance-companies-respective-cell-therapy-programs-in-oncology2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934/

Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.MONDAY, OCTOBER 14, 2019Shionogi & Co., Ltd. today announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. (Head Office: Media, PA, USA; President and CEO: William Claypool, M.D.; hereafter "Hsiri") regarding a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB). This new collaboration will include technology that complements Shionogi's earlier collaboration arrangement with Hsiri.The new technology to be licensed from Hsiri has a novel mechanism of action, will be complementary to Shionogi's current research with Hsiri, and is anticipated to be more effective than current therapies for mycobacterial infections. Shionogi's strength in small molecule drug discovery and development in the antibacterial area will support development of Hsiri's innovative therapeutics in this collaborative program. Under the terms of this agreement, Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialize the compounds generated from the collaboration. Hsiri will receive an upfront license fee, potential development milestones, and royalty payments based on sales from Shionogi.It is reported that the number of patients suffering from NTM diseases has been increasing, especially in developed countries, in recent years. There is a medical need to develop novel anti-NTM drugs because of the long duration of treatment and insufficient treatment outcome of current therapeutics. TB is one of the three major infectious diseases in the world, and new cases of TB are estimated to be 10.4 million/year. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) have become a major public health concern, and novel drugs for MDR-TB and XDR-TB are anticipated.Shionogi's research and development targets infectious disease as one of its priority areas, and Shionogi have positioned "protecting people from the threat of infectious diseases" as one of its social mission targets. Through this cooperation, Shionogi strives constantly to bring forth innovative drugs for the treatment of infectious diseases, to protect the health of patients we serve.information source:pharma focus AsiaThe original link:https:https:https://www.pharmafocusasia.com/news/shionogi-enters-into-a-new-license-agreement-and-research-collaboration-for-the-treatment-of-mycobacterial-diseases-with-hsiri-therapeutics-inc2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934/

Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery ResearchFRIDAY, OCTOBER 11, 2019Advaxis, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Company’s Lm technology in mouse tumor models of glioblastoma multiforme (GBM). Specifically, the collaboration with Dr. Vaithi Arumugaswami’s group at UCLA’s Department of Molecular and Medical Pharmacology will investigate anti-tumor immunity and anti-tumor responses generated by Lm vaccines that express diverse glioblastoma neoantigens.“We are excited that Dr. Arumugaswami and his colleagues at UCLA will investigate the potential of our Lm technology platform in GBM, one of the deadliest cancers,” said Andres Gutierrez, Executive Vice President and Chief Medical Officer of Advaxis. “Contrary to other tumor types, GBM has not seen much success in targeting by immunotherapeutic agents due to a low tumor mutation burden, high tumor heterogeneity and presence of the blood brain barrier, among other factors. Hence, Dr. Arumugaswami’s characterization of the neoantigen landscape and immune responses to Lm- constructs may lead to the development of novel therapies with clinical activity in this elusive cancer.”information source:pharma focus AsiaThe original link:https:https:https://www.pharmafocusasia.com/news/advaxis-and-ucla-enter-collaboration-for-glioblastoma-immunotherapy-discovery-research2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934/

THURSDAY, OCTOBER 10, 2019Viela Bio, Inc. and Mitsubishi Tanabe Pharma Corporation (“MTPC”) today announced a collaboration focused on the development and commercialization of inebilizumab – Viela’s humanized anti-CD19 monoclonal antibody – in nine Asia regions for neuromyelitis optica spectrum disorder (NMOSD), as well as other potential future indications.“This partnership adds to our ability to commercialize inebilizumab globally, subject to regulatory approval,” commented Bing Yao, Ph.D., Viela’s Executive Chairman and Chief Executive Officer. “As a well-established pharmaceutical company in Japan, Mitsubishi Tanabe has strong product development and commercialization capabilities in Asia, and we believe, is an ideal partner for expanding inebilizumab’s potential reach to thousands of additional patients in need of viable treatments, with NMOSD as an initial indication.”Under terms of the collaboration, Viela will receive an up-front licensing fee of $30 million as well as additional payments contingent on certain development and commercial milestones, plus payments based, in part, on sales revenue. MTPC will be responsible for leading development and commercialization of inebilizumab in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, Philippines, Singapore, and Taiwan.“Our organization is delighted to partner with Viela to develop and commercialize their promising product candidate inebilizumab for autoimmune and inflammatory diseases,” said Masayuki Mitsuka, MTPC President & Representative Director. “Inebilizumab is an exciting product candidate that, based on the results from the N-MOmentum pivotal study, is well-positioned to provide meaningful benefit for patients with NMOSD, and potentially additional diseases, subject to regulatory approval. We are excited to work with Viela to advance inebilizumab in Japan and other Asia regions, and look forward to a productive partnership between our companies.”The U.S. Food and Drug Administration (FDA) recently accepted for review Viela’s Biologics License Application (BLA) for inebilizumab for the treatment of NMOSD. information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/viela-bio-enters-strategic-collaboration-with-mitsubishi-tanabe-pharma-to-develop-and-commercialize-inebilizumab-for-autoimmune-diseases-in-japan-and-other-asia-regions2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934/

4D pharma plc, a leading pharmaceutical company in the development of live biotherapeutics, today announces that the company has entered into a research collaboration agreement and an option license to use with MSD (trading name of Merck & Co., Inc., in Kenilworth , New Jersey , United States of America) to Discover and Develop Live Biotherapeutic Products ("LBP") for vaccines.Under the terms of the agreement, MicroRx®, the proprietary platform of 4D, will be associated with MSD's expertise in the development and commercialization of new vaccines, in order to discover and develop LPBs as vaccines in maximum three undisclosed indications. 4D has the right, subject to certain conditions, to purchase from MSD for $ 5 million common shares of 4D during the first 12 months of the collaboration. In addition to an initial cash payment, for each indication, 4D will be eligible to receive up to $ 347.5 million in exercise of options and regulatory and development milestone payments, as well as royalties the annual net sales of any licensed product resulting from the collaboration.Duncan Peyton , CEO of 4D, said, "This collaborative research agreement brings together 4D's innovations in the microbiome field and MSD's track record in the development of advanced vaccines. MSD and 4D worked closely together combining world-class scientific knowledge to develop a work plan to advance understanding of this field, with the goal of generating a new class of vaccines in areas where unmet needs are important. "Daria Hazuda , Scientific Director of MSD's Exploratory Science Center and Vice President of Research on MSD's Infectious Diseases and Vaccines Discovery, said, "A key element of our goal at the Center for Exploratory Science is the assessment of emerging areas of emerging biology that are likely to have a major beneficial impact on human health. By applying MicroRx® technology of 4D, we hope to obtain useful information on the role of the host microbiome in modulating the immune response and, ultimately, the protection conferred by vaccines. "information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/4d-pharma-collaborates-with-msd-to-develop-live-biotherapeutic-products-for-vaccines2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934/

About Us
Contact Us
Zensee_Daystar online